Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers
Open Access
- 27 August 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 121 (12) , 2748-2752
- https://doi.org/10.1002/ijc.23037
Abstract
Family history of urogenital cancers has been associated with an increased risk of cancer at the same sites. To evaluate the risks of bladder, prostate and renal cell neoplasms for family history of urogenital cancers in first‐degree relatives, we analysed data from a case‐control study conducted in northern Italy between 1985 and 1992 and including a total of 1,356 incident, histologically confirmed cancer cases: 727 bladder, 348 renal cell and 281 prostate cancer cases. Controls were 1,067 patients admitted to the same network of hospitals for acute, nonneoplastic conditions. Unconditional logistic regression was used to estimate odds ratios (ORs) of urogenital cancers, adjusting for age, sex, study centre, education, body mass index, smoking habit, alcohol consumption and number of brothers and, where appropriate, sisters. ORs of urogenital cancers for subjects with at least 1 first‐degree relative with cancer at the same site were 6.1 [95% confidence interval (CI), 2.3–16.6] for bladder, 2.0 (95% CI: 0.6–6.2) for renal cell and 2.0 (95% CI: 0.9–4.1) for prostate cancer.Keywords
This publication has 93 references indexed in Scilit:
- Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial IssuesFrontiers in Oncology, 2013
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity CriteriaJNCI Journal of the National Cancer Institute, 2011
- Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancerBreast Cancer Research and Treatment, 2011
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationBreast Cancer Research and Treatment, 2009
- Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancerThe Journal of Pathology, 2009
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI Journal of the National Cancer Institute, 2007
- Family history of cancer provided by hospital controls was satisfactorily reliableJournal of Clinical Epidemiology, 2007
- Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritanceHuman Genetics, 2007
- Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationThe EMBO Journal, 2006